Comprehensive analysis of kinase inhibitor selectivity

Mindy I. Davis, Jeremy P. Hunt(National Institutes of Health), Sanna Herrgård, Pietro Ciceri(National Institutes of Health), Lisa Wodicka(National Institutes of Health), Gabriel Pallares(National Institutes of Health), Michael Höcker, Daniel K. Treiber(National Institutes of Health), Patrick P. Zarrinkar(National Institutes of Health)
Nature Biotechnology
October 30, 2011
10.1038/nbt.1990
Cited by 2,378Open Access
Full Text

Abstract

Related Papers

The Protein Kinase Complement of the Human Genome
Gerard Manning, D B Whyte, Robert A. Martinez et al.|Science|2002|8.1k
A small molecule–kinase interaction map for clinical kinase inhibitors
Miles A. Fabian, William Biggs, Daniel K. Treiber et al.|Nature Biotechnology|2005|1.9k
The specificities of protein kinase inhibitors: an update
Jenny Bain, Hilary McLauchlan, Matthew Elliott et al.|Biochemical Journal|2003|1.4k
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Marcus Bantscheff, Dirk Eberhard, Yann Abraham et al.|Nature Biotechnology|2007|1k
Targeting the cancer kinome through polypharmacology
Zachary A. Knight, Henry J. Lin, Kevan M. Shokat|Nature reviews. Cancer|2010|679